New clinical data continues to suggest that left atrial appendage occlusion devices may pose an improvement over warfarin drug regimens for treating patients at increased risk of stroke, researchers reported today.
Heart Rhythm Society
HRS14: St. Jude’s quadripolar pacing wins in 1st head-to-head study
The view from HRS 2014: This week at the Heart Rhythm Society’s 35th Annual Scientific Sessions
Things are still pretty quiet on opening day of Heart Rhythm 2014, the Heart Rhythm Society’s 35th Annual Scientific Sessions in semi-sunny San Francisco, but the week is shaping up to be a busy one.
There are few major announcements expected from this year’s sessions, but attendees are looking forward to some important updates on key new technologies and trends in cardiac pacing and electrophysiology, coming from the biggest players in the market.
HRS13: Arrhythmia Research Technology touts new ECG device
Arrhythmia Research Technology‘s (NYSE:HRT) Signal-Averaged Electrocardiography device is 1 of only 2 ECG tests that can predict ventricular arrhythmias in patients with prior heart attacks, data from an NIH-funded multi-center clinical trial proves.
HRS13: Endosense’s force-sensing ablation catheter
Geneva-based Endosense’s proprietary contact force technology improves efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, according to new study data released last week at the annual Heart Rhythm Society meeting.
On tap on Capitol Hill: The Medicare ‘doc fix’ | MassDevice.com On Call
MASSDEVICE ON CALL — The Senate Finance Committee will focus on how doctors are paid through Medicare, with a bipartisan pair of senior legislators looking for input from stakeholders.
Sens. Max Baucus (D-Mont.) and Orrin Hatch (R-Utah) asked healthcare providers last week for their views on repealing the "sustainable growth formula" that governs reimbursement rates at the Centers for Medicare & Medicaid Services (and which has been over-ruled by Congress dozens of times to avert pay cuts for physicians).
HRS2013: Sorin’s dual-chamber ICDs boast lower inappropriate shock rates
Patients with Sorin Group (BIT:SRN) dual-chamber implantable cardioverter defibrillators had significantly fewer inappropriate shocks than patients with standard single-chamber devices, according to new clinical data.
HRS2013: Boston Scientific touts battery life data
Recent study data proves longer battery life of Boston Scientific‘s (NYSE:BSX) implantable cardiac defibrillators and cardiac resynchronization therapy defibrillators, helping keep patients out of the hospital and reduce risk of infections and complications, the company claimed last week.
MassDevice.com +3 | The top 3 med-tech stories for May 13, 2013
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Heart Rhythm Society 2013 Scientific Session wrap-up
As the Heart Rhythm Society’s 2013 Scientific Sessions are a thing of the past, it is interesting to reflect on what constituted the main thrusts occurring our field. Summarizing thousands of abstracts and hundreds of sessions from scientists (literally) all over the world is impossible, of course. But it did appear a few sea changes in our field are in the works, at least as seen by this humble reporter.
HRS 2013 pre-meeting reflections
This morning I sit quietly in my hotel room, contemplating the day ahead at the 2013 Heart Rhythm Society Scientific Sessions in Denver. Emotions clash.